There is a moment, somewhere in the middle of a management presentation, when a founder realizes something has shifted. They have spent the last hour answering questions in a conference room full of people who arrived on a private flight and have never run a machine in their lives. The questions are good. The buyers have done their homework. And somewhere in the answering, the founder understands for the first time that this company they built is now, to these people, a financial instrument.
That moment is not a bad thing. But it surprises almost everyone who hasn't been through it before.
Selling a manufacturing business is one of the more complicated transactions a person can undertake. The process takes longer than most founders expect, costs more than most expect in time and attention, and surfaces surprises that almost no one expects. The goal of this article is to reduce the number of surprises — not by turning founders into bankers, but by describing, as plainly as possible, what actually happens.
The honest answer is: earlier than you are currently planning.
Mid-market M&A advisors at Grace Matthews, one of the most specialized chemical-sector advisory firms in the country, put the preparation window at 12 to 36 months before approaching buyers. The sale process itself — once you go to market — takes another 12 to 18 months. Add those together and you are looking at two to four years between "I'm thinking about selling" and "the wire hit."
Most founders don't plan that way. They plan around triggers: retirement age, a health event, a business plateau, an unsolicited call from a buyer. The problem with trigger-based timing is that it compresses the preparation window — and preparation is where the money is.
Kevin Yttre, president of Grace Matthews, describes a pattern where owners who wait for the right moment fall into a loop: "You can always find a reason to go, 'I'll just wait six more months.'" The result, often, is a missed window — or a rushed process that leaves value on the table.
Fewer than one in three small business owners have a documented exit plan, according to the Exit Planning Institute's 2023 National State of Owner Readiness Report. Among family-owned manufacturers with boomer owners, half have no succession plan at all. That is not a failure of intent. It is a failure of timing.
The businesses that sell well — that clear at good multiples, to buyers they chose, on terms they were satisfied with — almost always started preparing before they felt urgent pressure to.
The LOI is signed. You feel like the deal is done. It is not close to done.
Due diligence is the 60- to 90-day period after the Letter of Intent where the buyer verifies everything you have told them. For manufacturing businesses, this is the most demanding period of the entire process. Expect a data room request list running 200 to 500 items. Expect your CFO or controller to spend most of their working hours on diligence for months.
What gets examined:
Financials. Every line of the P&L and balance sheet. Revenue quality, customer concentration, margin trends, working capital patterns, capital expenditure history. The buyer will hire their own Quality of Earnings (QoE) firm to conduct an independent review of your financial statements.
The QoE is where founders encounter their first significant shock. Most manufacturing and chemical companies have run their books for tax minimization, not for a sale. The QoE adjusts for that — in both directions. Legitimate add-backs (above-market owner compensation, one-time costs, personal expenses through the business) can increase adjusted EBITDA by 10 to 30 percent. But the QoE also finds haircuts: revenue recognition timing issues, inventory obsolescence that's been sitting on the books at cost for years, cash-to-accrual adjustments that distort margins. For family chemical businesses going through this process for the first time, the net effect is almost always a downward adjustment to EBITDA — sometimes 15 to 25 percent. That adjustment flows directly through the multiple to your final number.
Working capital. At signing, the buyer and seller agree on a "peg" — a normalized level of working capital that will come with the business at close. This sounds straightforward. It is not. Chemical companies with seasonal inventory builds, lumpy receivables, or variable payables routinely end up in post-closing working capital disputes. These disputes cost sellers between $500,000 and $2 million or more in adjustments they never saw coming. Working capital is the single most commonly litigated element of manufacturing M&A deals.
Operations. Plant tours, equipment assessments, maintenance records, capacity utilization, supply chain analysis. Buyers want to understand what has been deferred and what it will cost to bring the facility to standard.
Environmental. Phase I and possibly Phase II environmental assessments. For chemical companies especially, this is where deals get complicated. Phase I is records review and site inspection. Phase II involves actual soil and groundwater sampling. Deals don't automatically die on Phase II findings — but they reprice, sometimes dramatically, and the structure shifts risk to the seller through indemnifications, escrows, and reduced proceeds. The specialty chemicals M&A pillar covers this dynamic in detail.
People. Org chart, compensation benchmarking, key-person identification, workforce tenure, union status. This is where something called key-person risk gets formally measured.
There is a specific moment in a management presentation that advisors talk about. The buyer's team asks a question — about a formulation, a customer relationship, a process parameter — and the only person in the room who can answer it is the owner. Then the buyer asks another question. Again, only the owner. Then another.
Omar Diaz of Balmoral Advisors has described what that sequence signals: "If we are in the room with all the top people, but the only one talking is the owner" — that is a key-person signal. It tells buyers that the organization has no depth, no independent management, and no transferable operation.
The financial consequence is measurable. Key-person risk applies a discount of 10 to 25 percent to enterprise value for private companies. In specialty chemicals and niche manufacturing, where customer relationships are often personal, technical knowledge is tacit, and the owner frequently handles pricing, quality, and major decisions personally, the discount tends toward the high end.
A business that generates $5 million in EBITDA, valued at 7x, is worth $35 million before any key-person adjustment. A 20 percent discount brings that to $28 million. That is a $7 million gap that costs nothing to start closing today — through documentation, management development, and deliberate delegation.
The specific mitigation that works: a named management team that can run the operation independently, standard operating procedures that capture tribal knowledge, cross-trained employees in essential roles, and evidence that customer relationships are serviced by non-owner staff. The question buyers are actually asking is: "How would this business run without you for 90 days?" The businesses that have a good answer to that question are more valuable than the ones that don't — independent of everything else.
The "Why We Only Buy Founder-Led Businesses" post discusses what this kind of tacit, embedded knowledge looks like from the buyer's perspective — why it is a genuine competitive asset, and why it needs to be transferred, not just admired.
This is the question most founders haven't thought carefully about — and the answer has changed significantly.
The buyer landscape for lower middle market manufacturing businesses has three main categories, and they operate differently in ways that matter:
Strategic buyers are larger companies in your industry or adjacent spaces. They buy capabilities, customers, and market position. They often pay the most because they capture synergies unavailable to financial buyers. The word "synergies," in practice, often means consolidation: your plant, your brand, and your workforce may not survive integration unchanged. Strategic buyers are the right home for founders who want the highest possible price and are genuinely comfortable with significant change to the business post-close.
Private equity uses investor capital to buy, grow, and sell businesses, typically in a three- to seven-year cycle. Larger PE funds have significant resources but operate under fund timelines that create their own pressures. Their incentive structure — buy, improve, exit — is not inherently misaligned with founders, but it produces a different kind of ownership than most founders have experienced.
Independent sponsors are a category that has grown substantially. There are now more than 1,500 active independent sponsors in the United States, a number that has roughly doubled in five years. As of 2025, independent sponsors represent 27 percent of lower middle market deal count — the single largest buyer category. An independent sponsor raises capital deal by deal, rather than deploying a pre-raised fund. That structure removes the fund clock from the equation, which changes how they think about holding periods, growth investments, and management continuity. The manufacturing M&A pillar has more on how the buyer mix has shifted and what it means for valuation.
The decision about which buyer type is right is not purely a financial one. Founders who have described their best outcome will talk about the check, but they will also talk about where their people landed and whether the business they built continued to function. Those outcomes are correlated with buyer type in ways worth understanding before the process starts.
Almost everything about the process surprises people who haven't been through it before. A few surprises are worth naming specifically because they are expensive and avoidable.
The country club multiple problem. Founders often arrive at a process with a number in their head. Usually, it came from a conversation at an industry conference or a round of golf with someone who sold recently: "I heard he got nine times." The problem is that "nine times" came with context that didn't travel with the number. That peer had three years of consistent EBITDA growth, audited financials, a management team that could run without him, no customer concentration, and 18 months of preparation. The multiple reflects all of that. The businesses that clear at 9x and the businesses that clear at 5x often look similar from the outside — the difference is in the data room.
The valuation gap on the QoE. As described above, the Quality of Earnings process almost always adjusts EBITDA downward from the number a founder walks in with. The adjustment is not a buyer trick. It is a methodological difference: founders have run their books for decades the way private businesses run their books. The QoE normalizes for that. Founders who understand this going in — who have done a sell-side QoE before going to market — are in a fundamentally different position than founders who encounter it for the first time as a buyer's weapon.
The earnout. When there is a gap between what a seller expects and what a buyer will pay at close, advisors sometimes suggest an earnout: a portion of the purchase price paid later, contingent on the business hitting targets post-close. Earnouts sound like a solution. According to SRS Acquiom data, earnouts achieve roughly 21 cents on the dollar on average, and are disputed 28 percent of the time. The problem is structural: after close, the buyer controls cost allocation, management priorities, and operational decisions. When the earnout metric is EBITDA, the buyer can influence it in ways the seller cannot. Earnouts are not always bad — but they deserve more skepticism than sellers typically bring to them.
The asset versus stock purchase question. Sellers generally prefer stock sales: they receive capital gains treatment, and the transaction is cleaner. Buyers generally prefer asset purchases, especially for chemical companies: an asset deal allows the buyer to avoid assuming unknown liabilities — particularly environmental ones — that travel with the legal entity in a stock purchase. This tension is not resolved at the term sheet stage. It plays out through the entire negotiation and has meaningful tax consequences for both sides. It is worth understanding before the first buyer conversation.
The environmental surprise. Many owners of manufacturing businesses — especially those on sites operated for 20 or 30 years — have never done environmental testing. They know they are in compliance because they have not been cited. That is not the same as being clean. Phase I findings lead to Phase II testing, which surfaces contamination that the seller genuinely didn't know existed. CERCLA, the federal environmental liability statute, imposes strict liability on current and former owners regardless of fault. The seller of a chemical facility is not necessarily off the hook because the contamination predates their ownership. This is worth knowing before due diligence surfaces it as a negotiating event.
"Surprises are only fun on your birthday." — Kevin Yttre, President, Grace Matthews
The purchase price is one number. The deal structure determines how much of it you actually receive, when, and under what conditions.
Escrows and holdbacks. It is standard for a portion of proceeds — typically 10 to 15 percent — to be held in escrow for 12 to 18 months post-close as a reserve against indemnification claims. This money is yours in all likelihood, but it is not liquid at close. Knowing this going in prevents a liquidity surprise on closing day.
Rollover equity. Buyers sometimes ask sellers to roll a portion of their equity into the new ownership structure — to retain "skin in the game" and align incentives through the next phase. Rollover is not inherently bad. It can produce significant additional returns if the buyer executes well. It is also illiquid, and it changes the seller's relationship with the business from former owner to minority stakeholder. The dynamics of that relationship are worth thinking about before agreeing to it.
Transition periods. Most deals require the seller to remain involved with the business for a defined period post-close — anywhere from six months to two or three years. The length and structure of that transition period often reflects how buyer-dependent the operation is. A business with strong management depth and documented processes may require a shorter transition; a business where the owner is the primary customer relationship may require a longer one.
Representation and warranty insurance (RWI). In the last decade, R&W insurance has moved from a specialty product to a standard feature of middle market M&A. The policy covers losses resulting from breaches of the seller's representations and warranties in the purchase agreement. For sellers, it means the escrow can often be structured around the insurance rather than held entirely from the seller's proceeds. For buyers, it provides a cleaner path to claims. Most sellers in deals of $20 million or more will encounter R&W insurance as part of the structure.
How do I know if I have a qualified buyer in front of me?
The basic signals: they have done comparable transactions, they can describe their capital structure clearly (for financial buyers, this means naming their equity source and having a relationship with a lender who does manufacturing deals), and they can answer questions about their diligence process without vagueness. Buyers who cannot describe their own process with specificity — who are "still working through the structure" weeks into initial conversations — are often less far along than they present. Qualified intermediaries who run competitive processes solve for this because they vet buyers before granting access.
What is the difference between an IOI and an LOI?
An Indication of Interest (IOI) is a non-binding expression of preliminary interest, typically submitted early in a process before detailed diligence. It names a valuation range and outlines broad deal structure. A Letter of Intent (LOI) is also typically non-binding on price, but it is more detailed, reflects more diligence, and usually includes an exclusivity period that prevents the seller from talking to other buyers while the deal is negotiated. Signing an LOI is a significant commitment even though it is not legally binding on the economics — it removes your leverage with competing buyers.
How do I handle employees finding out?
Most founders wait until the LOI is signed to inform the management team, and until closing to inform the broader workforce. That is the standard practice. It creates a period — often several months — where the seller and a small circle of advisors know, and nearly everyone else does not. Information does sometimes leak, particularly in small towns and tight-knit industries. The best preparation is having a clear plan for both announcements before you go to market: what you will say, who will say it, and in what order. Buyers understand this and can help structure the communication, but the plan should come from the seller.
What happens to my personal goodwill?
Personal goodwill — the value in customer relationships, reputation, and technical knowledge that belong to you as an individual rather than to the business entity — is a distinct legal and tax concept. In many manufacturing businesses, a meaningful portion of total enterprise value is personal goodwill. Its treatment in a deal has tax implications (personal goodwill can sometimes be taxed at capital gains rates rather than ordinary income) and practical implications (buyers want to ensure it transfers). How this is handled should be part of the pre-process planning conversation with your tax advisor and M&A counsel, not something figured out at the closing table.
What is a sell-side QoE and do I need one?
A sell-side QoE is a Quality of Earnings report commissioned by the seller, before going to market, using a third-party accounting firm. It gives the seller advance notice of the adjustments a buyer's QoE will find — the add-backs, the haircuts, and the working capital dynamics — so none of it is a surprise. It also lets the seller present a defensible adjusted EBITDA number from day one, with supporting documentation, rather than negotiating it under pressure during due diligence. Not every deal requires a sell-side QoE, but for businesses with complex financials, owner add-backs, or inventory-heavy balance sheets, it is worth the cost in advance of the process.
How do I think about the "right" multiple for my business?
The valuation multiples you see in industry reports reflect a range of deal types, sizes, buyer categories, and market conditions. For specialty chemical companies, the current chemicals M&A market analysis puts the market average at 9.0x EBITDA, with PE transactions on quality assets clearing 12.2x. For niche manufacturers, the manufacturing M&A landscape post shows lower middle market deals clearing 5.8x on average, with significant premium for automation, certifications, and end-market exposure. These are reference points, not promises. The multiple any specific business receives reflects its size, growth trajectory, customer concentration, management depth, documentation, and the specific buyers it attracts. The gap between 5x and 9x is rarely in the income statement — it is in the variables that affect how a buyer underwrites risk.
"Uncertainty is the enemy of M&A. You can navigate through certain dynamics, but when uncertainty increases, it becomes more and more challenging." — Jon Glapa, Grace Matthews
HarborWind has been on both sides of this table. We have been operators and we have been buyers. The founders we have respected most in this process are the ones who walked in knowing what they didn't know — who came to diligence with documented answers and disclosed their issues before we found them, because they understood that the deal they wanted required trust, and trust requires transparency.
The founders who struggled were the ones who came in with a number they couldn't defend, processes they couldn't explain, and surprises they hoped wouldn't surface. Surprises surface. The buyers who find them respond predictably.
The businesses that sell well are not necessarily the ones with the best financials. They are the ones where the founder put in the work before the process started — to document what was in their heads, to build the team that could run without them, to clean up the issues they already knew about, and to understand the market they were entering before they entered it.
That preparation is not a gift to the buyer. It is a gift to the deal — and to themselves.
For more on the specialty chemicals M&A environment, see The State of M&A for Specialty Chemical Companies. For more on niche manufacturing valuations, see The State of M&A for Niche Manufacturers. On why knowledge documentation matters to buyers, see The Formulation Book as a Depreciating Asset.
For HarborWind's full thesis on what makes the right long-term buyer for a founder-led business, see Why We Buy Founder-Led Industrial Businesses.
Buy. Build. Compound.